miR-31与宫颈癌淋巴转移的相关性研究

Study of miR-31 in cerivical cancer with lymph node metastasis

目的:研究微RNAs(miRNAs)差异表达与宫颈癌淋巴转移的关系,寻找早期预测淋巴转移的分子标志物及判断患者预后的指标,探讨宫颈癌淋巴转移可能的作用机制。方法:应用安捷伦(Agilent)Human miRNAs V16.0基因芯片检测宫颈癌淋巴转移组与非淋巴转移组的差异表达miRNAs基因,筛选宫颈癌淋巴转移相关miRNAs,并采用实时荧光PCR技术(Real-time PCR)验证芯片结果的准确性,用生物信息学法分析其作用靶点。结果:宫颈癌淋巴转移组中,共筛选出3个显著下调的miRNAs(P<0.05):hsa-miR-31、hsa-miR-31*、hsa-let-7d。其中,hsa-miR-31是宫颈癌淋巴转移组下调最显著的miRNAs。实时荧光PCR验证结果与芯片结果基本吻合。结论:hsa-miR-31抑制肿瘤细胞生长、迁移,在淋巴转移宫颈癌组织中的表达明显下调,它可能成为宫颈癌淋巴转移的分子标志物及治疗靶点。

Objective：To investigate the correlation between differential expression of microRNAs（miRNAs） and lymph node metastasis in cervical cancer. Methods：Using Agilent Human miRNAs V16.0 gene chips to identify the differential expression of miRNAs in cervical cancer with lymph node metastasis and without lymph nodemetastasis. Using Real-time PCR to detect the expression of miRNAs. Using bioinformatics to predict the target genes of miR-31. Results：There were three differential expressed miRNAs in cervical cancer with lymph node metastasis and those without lympth node metastasis： hsa-miR-31, hsa-miR-31 ＊ , and hsa-let- 7d. The results of Real-time PCR showed that Hsa-miR-31 was down-regulated markedly in cer- vical cancer with lymph node metastasis. Conclusions：Hsa-miR-31 repressed tumor growth and dissemination, down-regulated markedly in cervical cancer with lymph node metastasis and may likely become the marker of predicting lymph node metastasis and therapeutic target gene in cervical cancer.